FDA Approval of Daraxonrasib in Pancreatic Cancer

Dr Balmaceda, a gastrointestinal medical oncologist at MD Anderson Cancer Center, frames the recent US Food and Drug Administration approval of daraxonrasib, a multi-selective inhibitor of the active form of RAS and the first pan-RAS targeted therapy cleared for metastatic pancreatic cancer, against the narrower allele-selective approach represented by sotorasib and adagrasib. Dr Lee, a gastrointestinal medical oncologist at Stanford University, says he cannot overstate the impact of the approval, calling it a paradigm shift that opens new treatment strategies and revives previously ineffective ones. He describes the registrational trial, which randomized patients with previously treated metastatic pancreatic cancer to daraxonrasib or investigator's choice chemotherapy and did not require a RAS mutation for entry, and reports that it met both its overall survival and progression-free survival endpoints while delivering more durable pain control and better quality of life. Dr Balmaceda previews first-line and adjuvant trials, KRAS vaccines, and known resistance mechanisms.